Phase II Trial of Phenoxodiol in Recurrent Ovarian Cancer Is launched

January 1, 2003
Oncology NEWS International, Oncology NEWS International Vol 12 No 1, Volume 12, Issue 1

WASHINGTON-Marshall Edwards, Inc. has launched a multi-center phase II clinical trial of its anticancer drug phenoxodiol in women with recurrent ovarian and fallopian tube cancers who have failed other forms of chemotherapy.

WASHINGTON—Marshall Edwards, Inc. has launched a multi-center phase II clinical trial of its anticancer drug phenoxodiol in women with recurrent ovarian and fallopian tube cancers who have failed other forms of chemotherapy.

A damaged cell normally shuts off production of the antiapoptotic proteins FLIP and XIAP to allow activation of the apoptosis-triggering receptors (Fas, TNFR1, DR3, TRAIL). Cancer cells resist this process by producing large amounts of blocking proteins such as FLIP. Phenoxodiol blocks FLIP and XIAP in cancer cells without harming noncancer cells, the company said in a news release.